FibroGen, Inc.
FGEN
$6.89
-$0.03-0.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -89.20% | 104.25% | 15.45% | 14.26% | -29.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.20% | 104.25% | 15.45% | 14.26% | -29.86% |
| Cost of Revenue | -83.70% | -97.97% | -58.73% | -61.18% | -25.83% |
| Gross Profit | 79.40% | 101.70% | 176.39% | 119.97% | 22.36% |
| SG&A Expenses | -51.50% | 283.57% | -31.36% | -28.56% | -51.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.48% | -79.60% | -51.04% | -53.49% | -33.59% |
| Operating Income | 69.92% | 94.79% | 103.49% | 87.60% | 35.36% |
| Income Before Tax | 65.81% | 90.89% | 73.13% | 82.02% | 36.01% |
| Income Tax Expenses | -71.43% | 101.14% | -85.71% | -11.49% | -90.54% |
| Earnings from Continuing Operations | 65.82% | 90.88% | 73.14% | 82.27% | 36.06% |
| Earnings from Discontinued Operations | 32.84% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 114.09% | 131.98% | 73.14% | 82.27% | 57.07% |
| EBIT | 69.92% | 94.79% | 103.49% | 87.60% | 35.36% |
| EBITDA | 70.09% | 95.01% | 105.19% | 88.12% | 33.86% |
| EPS Basic | 113.83% | 131.38% | 73.75% | 82.65% | 58.93% |
| Normalized Basic EPS | 66.73% | 93.70% | 102.84% | 82.39% | 38.57% |
| EPS Diluted | 113.83% | 131.38% | 73.75% | 82.65% | 58.93% |
| Normalized Diluted EPS | 66.73% | 93.70% | 102.84% | 82.39% | 38.57% |
| Average Basic Shares Outstanding | 1.99% | 3.62% | 2.31% | 2.15% | 4.53% |
| Average Diluted Shares Outstanding | 1.99% | 3.62% | 2.31% | 2.15% | 4.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |